Characterization and high‐yield production of non‐N‐glycosylated recombinant human BCMA‐Fc in Pichia pastoris
Sign Up to like & getrecommendations! Published in 2017 at "Engineering in Life Sciences"
DOI: 10.1002/elsc.201600039
Abstract: B‐cell maturation antigen (BCMA) fused at the C‐terminus to the Fc portion of human IgG1 (BCMA‐Fc) blocks B‐cell activating factor (BAFF) and proliferation‐inducing ligand (APRIL)‐mediated B‐cell activation, leading to immune disorders. The fusion protein has… read more here.
Keywords: recombinant human; production; bcma; human bcma ... See more keywords
Comparative efficacy and safety of BCMA-targeted CAR T cells and BiTEs in relapsed/refractory multiple myeloma: a meta-analysis of interventional and real-world studies
Sign Up to like & getrecommendations! Published in 2025 at "Annals of Hematology"
DOI: 10.1007/s00277-025-06524-6
Abstract: Despite therapeutic advances, multiple myeloma (MM) remains incurable, especially in relapsed/refractory (R/R) cases. B-cell maturation antigen (BCMA) is a key target for novel immunotherapies, including chimeric antigen receptor T-cell (CAR-T) therapies and bispecific T-cell engagers… read more here.
Keywords: bcma; meta analysis; car therapies; efficacy ... See more keywords
The Role of B-Cell Maturation Antigen in the Biology and Management of, and as a Potential Therapeutic Target in, Multiple Myeloma
Sign Up to like & getrecommendations! Published in 2017 at "Targeted Oncology"
DOI: 10.1007/s11523-017-0538-x
Abstract: B-cell maturation antigen (BCMA) was originally identified as a cell membrane receptor, expressed exclusively on late stage B-cells and plasma cells (PCs). Investigations of BCMA as a target for therapeutic intervention in multiple myeloma (MM)… read more here.
Keywords: bcma; target; biology; antigen ... See more keywords
Selective targeting of multiple myeloma by B cell maturation antigen (BCMA)-specific central memory CD8+ cytotoxic T lymphocytes: immunotherapeutic application in vaccination and adoptive immunotherapy
Sign Up to like & getrecommendations! Published in 2019 at "Leukemia"
DOI: 10.1038/s41375-019-0414-z
Abstract: To expand the breadth and extent of current multiple myeloma (MM)-specific immunotherapy, we have identified various antigens on CD138+ tumor cells from newly diagnosed MM patients (n = 616) and confirmed B-cell maturation antigen (BCMA) as a… read more here.
Keywords: bcma specific; myeloma; bcma; memory cd8 ... See more keywords
Single VHH-directed BCMA CAR-T cells cause remission of relapsed/refractory multiple myeloma
Sign Up to like & getrecommendations! Published in 2021 at "Leukemia"
DOI: 10.1038/s41375-021-01269-3
Abstract: Chimeric antigen receptor T (CAR-T) cells have shown remarkable effects in treating hematological malignancies [1, 2]. Typically, the antigen recognition domain of CAR-T cells is a single-chain variable fragment (scFv) linked to a costimulatory domain… read more here.
Keywords: chain; heavy chain; bcma; vhh ... See more keywords
Plasmapheresis facilitates soluble BCMA clearance and contributes to reversing primary resistance to anti-BCMA immunotherapy in multiple myeloma
Sign Up to like & getrecommendations! Published in 2025 at "Leukemia"
DOI: 10.1038/s41375-025-02757-6
Abstract: Introduction: Despite potent efficacy of bispecific antibodies against the B-cell maturation antigen (BCMA) in multiple myeloma (MM), primary resistance may occur in as many as 40% of patients. Known resistance mechanisms include antigen loss, epigenetic… read more here.
Keywords: bcma; anti bcma; sbcma; plasmapheresis ... See more keywords
CXCR4 and anti-BCMA CAR co-modified natural killer cells suppress multiple myeloma progression in a xenograft mouse model.
Sign Up to like & getrecommendations! Published in 2021 at "Cancer gene therapy"
DOI: 10.1038/s41417-021-00365-x
Abstract: The highly restricted expression of B-cell maturation antigen (BCMA) on plasma cells makes it an ideal target for chimeric antigen receptor (CAR) immune cell therapy against multiple myeloma (MM), a bone marrow cancer. To improve… read more here.
Keywords: bcma; natural killer; multiple myeloma; cxcr4 ... See more keywords
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
Sign Up to like & getrecommendations! Published in 2024 at "Nature Communications"
DOI: 10.1038/s41467-024-44873-4
Abstract: BCMA-specific CAR T-cell therapies have shown high response rates in multiple myeloma (MM), however the majority of patients still relapse. Here the authors show that CD24-positive MM cells increase after BCMA-CAR-T treatment in patients, and… read more here.
Keywords: bcma; cd24 car; car; car cells ... See more keywords
TSCM-predominant allogeneic anti-BCMA CAR-T therapy for relapsed/refractory multiple myeloma: preclinical characterization and interim results from a phase 1 trial
Sign Up to like & getrecommendations! Published in 2025 at "Nature Communications"
DOI: 10.1038/s41467-025-65267-0
Abstract: Autologous CAR-T therapies targeting B-cell maturation antigen (BCMA) in relapsed/refractory multiple myeloma (RRMM) have demonstrated therapeutic clinical responses. Here, we present the characterization and interim Phase I data for P-BCMA-ALLO1, a TSCM-predominant allogeneic CAR-T therapy… read more here.
Keywords: bcma; multiple myeloma; therapy; car therapy ... See more keywords
Soluble TACI and soluble BCMA as biomarkers in primary central nervous system lymphoma
Sign Up to like & getrecommendations! Published in 2017 at "Neuro-Oncology"
DOI: 10.1093/neuonc/nox097
Abstract: Background B-cell survival is regulated through interactions of B-cell-activating factor and a proliferation-inducing ligand with their receptors transmembrane activator and CAML interactor (TACI) and B-cell maturation antigen (BCMA). We evaluated the diagnostic potential of soluble… read more here.
Keywords: soluble bcma; soluble taci; bcma; sbcma ... See more keywords
Anti-BCMA CAR-T cells therapy for a patient with extremely high membrane BCMA expression: a case report
Sign Up to like & getrecommendations! Published in 2022 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2022-005403
Abstract: B cell maturation antigen (BCMA)-directed CAR-T cell therapy is a disruptive approach for treating relapsed/refractory multiple myeloma (R/R MM); however, optimization is necessary to maximize patient benefit. We report the case of a 61-year-old woman… read more here.
Keywords: bcma; expression; case; membrane bcma ... See more keywords